Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factors

Abstract Augmented renal clearance (ARC) is a phenomenon that has been associated with enhanced excretion of renally eliminated drugs, such as antimicrobials, which may result in subtherapeutic levels and potentially therapeutic failure. There has been limited data on ARC in critically ill patients...

Full description

Bibliographic Details
Main Authors: Lama H. Nazer, Aseel K. AbuSara, Yasmeen Kamal
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Pharmacology Research & Perspectives
Subjects:
Online Access:https://doi.org/10.1002/prp2.747
_version_ 1818918493915971584
author Lama H. Nazer
Aseel K. AbuSara
Yasmeen Kamal
author_facet Lama H. Nazer
Aseel K. AbuSara
Yasmeen Kamal
author_sort Lama H. Nazer
collection DOAJ
description Abstract Augmented renal clearance (ARC) is a phenomenon that has been associated with enhanced excretion of renally eliminated drugs, such as antimicrobials, which may result in subtherapeutic levels and potentially therapeutic failure. There has been limited data on ARC in critically ill patients with cancer. This study aimed to evaluate the prevalence of ARC and to identify risk factors associated with ARC in this patient population. This was a prospective study at an oncologic intensive care unit (ICU) which included adult patients with normal renal function, defined as serum creatinine ≤1 mg/dl and urine output >0.5 ml/kg/hr. The 24‐hour creatinine clearance (ClCr) study was used to determine ClCr, starting on day 1 of ICU admission, for 5 days or until ICU transfer or death. ARC was defined as ClCr >130 ml/min/1.73 m2. Univariate and multivariate logistic regression analyses were performed to identify risk factors for ARC. Over the study period, 363 patients were enrolled who completed an average of 2.8 ± 1.5(SD) days in the study and contributed 977 ClCr measurements. The mean age was 52 ± 16(SD) years old, the majority had solid tumors (n = 264, 73%), mean APACHE II was 21 ± 8(SD), and the major admission diagnosis was respiratory failure (n = 165, 45%). ARC was reported in 116 (32%) patients on at least one of the study days. Over the study period, the incidence of ARC ranged between 15.6% and 24.3%. Age was the only risk factor significantly associated with ARC (OR 1.028, 95% CI 1.005–1.051).
first_indexed 2024-12-20T00:50:51Z
format Article
id doaj.art-764b323b23e54121a48c92ece4c5b972
institution Directory Open Access Journal
issn 2052-1707
language English
last_indexed 2024-12-20T00:50:51Z
publishDate 2021-04-01
publisher Wiley
record_format Article
series Pharmacology Research & Perspectives
spelling doaj.art-764b323b23e54121a48c92ece4c5b9722022-12-21T19:59:15ZengWileyPharmacology Research & Perspectives2052-17072021-04-0192n/an/a10.1002/prp2.747Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factorsLama H. Nazer0Aseel K. AbuSara1Yasmeen Kamal2Department of Pharmacy King Hussein Cancer Center Amman JordanDepartment of Pharmacy King Hussein Cancer Center Amman JordanDepartment of Pharmacy King Hussein Cancer Center Amman JordanAbstract Augmented renal clearance (ARC) is a phenomenon that has been associated with enhanced excretion of renally eliminated drugs, such as antimicrobials, which may result in subtherapeutic levels and potentially therapeutic failure. There has been limited data on ARC in critically ill patients with cancer. This study aimed to evaluate the prevalence of ARC and to identify risk factors associated with ARC in this patient population. This was a prospective study at an oncologic intensive care unit (ICU) which included adult patients with normal renal function, defined as serum creatinine ≤1 mg/dl and urine output >0.5 ml/kg/hr. The 24‐hour creatinine clearance (ClCr) study was used to determine ClCr, starting on day 1 of ICU admission, for 5 days or until ICU transfer or death. ARC was defined as ClCr >130 ml/min/1.73 m2. Univariate and multivariate logistic regression analyses were performed to identify risk factors for ARC. Over the study period, 363 patients were enrolled who completed an average of 2.8 ± 1.5(SD) days in the study and contributed 977 ClCr measurements. The mean age was 52 ± 16(SD) years old, the majority had solid tumors (n = 264, 73%), mean APACHE II was 21 ± 8(SD), and the major admission diagnosis was respiratory failure (n = 165, 45%). ARC was reported in 116 (32%) patients on at least one of the study days. Over the study period, the incidence of ARC ranged between 15.6% and 24.3%. Age was the only risk factor significantly associated with ARC (OR 1.028, 95% CI 1.005–1.051).https://doi.org/10.1002/prp2.747augmented renal clearancecancercritical illnessICUoncology
spellingShingle Lama H. Nazer
Aseel K. AbuSara
Yasmeen Kamal
Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factors
Pharmacology Research & Perspectives
augmented renal clearance
cancer
critical illness
ICU
oncology
title Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factors
title_full Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factors
title_fullStr Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factors
title_full_unstemmed Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factors
title_short Augmented renal clearance in critically ill patients with cancer (ARCCAN Study): A prospective observational study evaluating prevalence and risk factors
title_sort augmented renal clearance in critically ill patients with cancer arccan study a prospective observational study evaluating prevalence and risk factors
topic augmented renal clearance
cancer
critical illness
ICU
oncology
url https://doi.org/10.1002/prp2.747
work_keys_str_mv AT lamahnazer augmentedrenalclearanceincriticallyillpatientswithcancerarccanstudyaprospectiveobservationalstudyevaluatingprevalenceandriskfactors
AT aseelkabusara augmentedrenalclearanceincriticallyillpatientswithcancerarccanstudyaprospectiveobservationalstudyevaluatingprevalenceandriskfactors
AT yasmeenkamal augmentedrenalclearanceincriticallyillpatientswithcancerarccanstudyaprospectiveobservationalstudyevaluatingprevalenceandriskfactors